G6PD Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Alerts
• Clinical Trials
• Forums

Evaluation of the Safety of Primaquine in Combination With Dihydroartemisinin-piperaquine in G6PD Deficient Males in The Gambia
Condition:   MalariaInterventions:   Drug: Dihydroartemisinin-piperaquine (DHAP) administered to G6PD deficient individuals;   Drug: Dihydroartemisinin-piperaquine (DHAP) + 0.25 mg/kg primaquine administered to G6PD deficient individuals;   Drug: Dihydroartemisinin-piperaquine (DHAP) + 0.4 mg/kg primaquine administered to G6PD deficient individuals;   Drug: Dihydroartemisinin-piperaquine (DHAP) + 0.25 mg/kg primaquine administered to G6PD normal individuals;   Drug: Dihydroartemisinin-piperaquine (DHAP) + 0.4 mg/kg primaquine administered to G6PD normal individualsSponsors:   London School of Hygiene and Tro...
Source: ClinicalTrials.gov - January 5, 2016 Category: Research Source Type: clinical trials